Logo

The US FDA Grants Breakthrough Device Designation to AbSolutions Med’s Rebuild Bioabsorbable Abdominal Wall Closure Device for Incisional Hernia

Share this
AbSolutions Med

The US FDA Grants Breakthrough Device Designation to AbSolutions Med’s Rebuild Bioabsorbable Abdominal Wall Closure Device for Incisional Hernia

Shots:

  • The company has received Breakthrough Device Designation from the US FDA for its Rebuild Bioabsorbable (REBUILD) abdominal wall closure device for incisional hernia
  • REBUILD enables abdominal wall closure by distributing suture tension and maintaining midline fascial structure apposition during the healing process after surgery. It is absorbed to lower the long-term foreign body complication risk
  • REBUILD is being investigated in a prospective, multicenter, single-arm trial for closure of the abdominal wall after oncologic laparotomy

Ref: AbSolutions Med | Image: AbSolutions Med

Related News:- Innocoll's Xaracoll (bupivacaine HCl) Receives the US FDA's Approval for the Acute Postsurgical Pain Relief in Adults Following Open Inguinal Hernia Repair

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions